3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Neoplasms
10
Melanoma
9
Lung Neoplasms
8
Breast Neoplasms
8
Multiple Myeloma
7
Leukemia, Myeloid, Acute
7
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Brain Neoplasms
5
Myelodysplastic Syndromes
4
Lymphoma, Non-Hodgkin
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Endometrial Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Carcinoma, Transitional Cell
3
Carcinoma, Renal Cell
3
Thyroid Neoplasms
2
Interventions
durvalumab
1
Oxaliplatin
1
Leucovorin
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease Progression
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts